NCT/Study#
NCT04546399 /
COG-AALL1821
CIRB/COG AALL1821: A Phase 2 Study of Blinatumomab (NSC# 765986, IND# 125462) in Combination with Nivolumab (NSC# 748726, IND# 125462),a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged ≥1 to <31 Years Old with First Relapse
DISEASE GROUP:
Pediatric Oncology
current phase:
Phase II
STUDY STATUS:
Enrolling
Location:
Hackensack, NJ
For More information:
